Strong growth of Key Products and in most emerging markets was partly offset by the negative impact of pantoprazole's patent expiry in Europe, the economic downturn and adverse currency fluctuations.

Total net turnover decreased 3.6% (-0.6% in local currencies and excluding one-time effects) to €3,228.0 million (FY/2008: €3,348.0 million). In the fourth quarter, total net turnover decreased 4.9% (-0.4% on a comparable basis) to €781.1 million (Q4/2008: €821.1 million). Adjusted EBITDA decreased 11.0% (-3.8% in local currencies and excluding one-time effects) to €1,074.6 million (FY/2008: €1,207.6 million). In the fourth quarter, adjusted EBITDA decreased 14.5% (-3.9% on a comparable basis) to €221.8 million (Q4/2008: €259.5 million).

Pantoprazole sales resilient despite loss of exclusivity in May. Newly-launched OTC variant performing strongly in Europe. Roflumilast submitted to EMEA and FDA for treatment of COPD. Agreement with Forest Laboratories on US commercialisation signed. Positive phase III trial results published in the medical journal The Lancet. Instanyl^® for breakthrough cancer pain launched in Europe in September with very positive market response.

Click here to read the entire press release on Nycomed.com